Clinical trials: Healthy Controls
- Condition Healthy Controls
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Healthy Volunteer, Muscular Atrophy, Spinal
Ability of Muscle Imaging and Motor Function Measure (MFM) to Detect Changes in Disease Progression in Ambulant Spinal Muscular Atrophy Patients Compared to Healthy Volunteers.
This non-drug, single center, 24-week, longitudinal study in ambulant spinal muscular atrophy (SMA) patients and in age- and gender-matched healthy volunteers will assess the detection of disease progression by magnetic resonance…
- Trial name
- NCT02044029
- Where
- Switzerland
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Healthy Controls
Normative Data of Brain Network Activation in Adolescents and Young Adults
Establish normative data of ElMindA's Brain Network Activation (BNA) using evoked response in two age groups: adolescents and young adults.
- Trial name
- NCT01671761
- Where
- United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- ElMindA Ltd
Infections, Meningococcal
Combined Study - Phase 3b MenB Long Term Persistence in Adolescents
The purpose/aim of this study is to assess 1) the long-term persistence (4 to 7.5 years after the last dose) of bactericidal activity following primary vaccination with rMenB+OMV NZ in adolescents [who previously participated in…
- Trial name
- NCT02446743
- Testing
- rMenB+OMV NZ (Meningococcal (Group B) multi component recombinant adsorbed vaccine)
- Where
- 12 sites in Australia, Canada and 1 more
- Volunteers
- 531 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy Controls
Normative Data of Brain Network Activation in Adolescents and Young Adults
Establish normative data of ElMindA's Brain Network Activation (BNA) using evoked response in two age groups: adolescents and young adults.
- Trial name
- NCT01460394
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- ElMindA Ltd
PCD
NIOX VERO Nasal Application in Primary Ciliary Dyskinesia
This is a multi-centre, single visit clinical investigation involving patients with known PCD vs. age matched healthy volunteers. This study involves 1 visit which will last one (1) to two (2) hours.
- Trial name
- NCT02622061
- Where
- 5 sites in United States, Denmark and 2 more
- Volunteers
- 163 people, healthy volunteers welcome
- Sponsor
- Aerocrine AB
Meningococcal Disease
Safety and Immunogenicity of Novartis Meningococcal B Vaccine When Administered to Immunocompromised Children and Adolescents Compared to Healthy Subjects.
The study aims at evaluating the safety and immunogenicity of rMenB+OMV NZ when administered to subjects from 2 to 17 years of age with increased risk of meningococcal disease because either of primary or secondary complement…
- Trial name
- NCT02141516
- Testing
- rMenB+OMV
- Where
- 20 sites in Italy, Poland and 3 more
- Volunteers
- 239 people, healthy volunteers welcome
- Sponsor
- Novartis
Healthy Controls
Normative Data of Brain Network Activation
Establish normative data of ElMindA's Brain Network Activation (BNA) using evoked response in three age groups.
- Trial name
- NCT01742858
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- ElMindA Ltd
Healthy Controls, Brain Function
NeuroCatch Reference Interval Database
The purpose of this study is to understand how the brain responds to sounds and words, and how this response varies between individuals.
- Trial name
- RR (NCT06677424)
- Testing
- NeuroCatch® Platform 2
- Where
- Canada
- Volunteers
- 224 people, healthy volunteers welcome
- Sponsor
- HealthTech Connex Inc.